Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Revance Therapeutics (RVNC – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at $6.31.
According to TipRanks, Samimy is a 4-star analyst with an average return of 6.7% and a 47.76% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Inventiva, and Cara Therapeutics.
In addition to Stifel Nicolaus, Revance Therapeutics also received a Buy from Needham’s Serge Belanger in a report issued on January 9. However, on the same day, Goldman Sachs downgraded Revance Therapeutics (NASDAQ: RVNC) to a Hold.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $37.98 and a one-year low of $5.72. Currently, Revance Therapeutics has an average volume of 1.71M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics (RVNC) Company Description:
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
Read More on RVNC:
